From peptide to non-peptide. 3. Atropisomerie GPIIbIIIa antagonists containing the 3,4-dihydro-1H-1,4-benzodiazepine-2,5-dione nucleus

Journal of Medicinal Chemistry

Volumn 40, Issue 5, 1997, Pages 717-729

  Blackburn, Brent K ^a   Lee, Arthur ^a   Baier, Mark ^a   Kohl, Benjamin ^a   Olivero, Alan G ^a   Matamoros, Regina ^a   Robarge, Kirk D ^a   McDowell, Robert S ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DIHYDRO 1H 1,4 BENZODIAZEPINE 2,5 DIONE DERIVATIVE; BENZODIAZEPINE DERIVATIVE; FIBRINOGEN RECEPTOR; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; CRYSTAL STRUCTURE; ENANTIOMER; PROTEIN CONFORMATION; RECEPTOR BINDING; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; THROMBOCYTE AGGREGATION;

BENZODIAZEPINONES; CRYSTALLOGRAPHY, X-RAY; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MOLECULAR STRUCTURE; PEPTIDES, CYCLIC; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0031040820     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm960652r     Document Type: Article

References (49)

1. Plow, E. F.; Pierschbacher, M. D.; Ruoslahti, E.; Marguerie, G. A.; Ginsberg, M. H. The Effect of Arg-Gly-Asp-Containing Peptides on Fibrinogen and von Willebrand Factor binding to Platelets. Proc. Natl. Acad. Sci. U.S.A. 1985, 82, 8057.
2. Bennett, J. S.; Hoxie, J. A.; Leitman, S. F. Inhibition of Fibrinogen Binding to Stimulated Human Platelets by a Monoclonal Antibody. Proc. Natl. Acad. Sci. U.S.A. 1983, 80, 2417.
3. Coller, B. S. Antiplatelet Agents in the Prevention and Therapy of Thrombosis. Annu. Rev. Med. 1992, 43, 171.
4. Zablocki, J. A.; Rao, S. N.; Baron, D. A.; Flynn, D. L.; Nicholson, N. J.; Feigen, L. P. Fibrinogen Receptor Antagonists. Curr. Pharm. Des. 1995, 1, 533-558.
5. Barker, P. L.; Bullens, S.; Bunting, S.; Burdick, D. J.; Chan, K. S.; Deisher, T.; Eigenbrot, C.; Gadek, T. R.; Gantzos, R.; Lipari, M. T.; Muir, C. D.; Napier, M. A.; Pitti, R. M.; Padua, A.; Quan, C.; Stanley, M.; Struble, M.; Tom, J. Y. K.; Burnier, J. P. Cyclic RGD Peptide Analogues as Antiplatelet Antithrombotics. J. Med. Chem. 1992, 35, 2040.
6. McDowell, R. S.; Gadek, T. R. Structural Studies of Potent Constrained RGD Peptides. J. Am. Chem. Soc. 1992, 114, 9245.
7. McDowell, R. S.; Gadek, T. R.; Barker, P. L.; Burdick, D. J.; Chan, K. S.; Quan, C. L.; Skelton, N.; Struble, M.; Thorsett, E. D.; Tishler, M.; Tom, J. Y. K.; Webb, T. R.; Burnier, J. P. From Peptide to Non-peptide. 1. The Elucidation of a Bioactive Conformation of the Arginine-Glycine-Aspartic Acid Recognition Sequence. J. Am. Chem. Soc. 1994, 116, 5069.
8. McDowell, R. S.; Blackburn, B. K.; Gadek, T. R.; McGee, L. R.; Rawson, T.; Reynolds, M. E.; Robarge, K. D.; Somers, T. C.; Thorsett, E. D.; Tishler, M.; Webb, R. R.; Venuti, M. C. From Peptide to Non-peptide. 2. The de novo Design of Potent, Nonpeptidal Inhibitors of Platelet Aggregation Based on a Benzodizepinedione Scaffold. J. Am. Chem. Soc. 1994, 116, 5077.
9. Kodandapani, R.; Veerapandian, B.; Kunicki, T. J.; Ely, K. R. Crystal Structure of the OPG2 Fab. J. Biol. Chem. 1995, 270, 2268-2273.
10. Lee, G.; Chan, W.; Hurle, M. R.; DesJarlais, R. L.; Watson, F.; Sathe, G. M.; Wetzel, R. Strong Inhibition of Fibrinogen Binding to Platelet Receptor to Platelet Receptor αIIbβ3 by RGD Sequences Installed Into a Presentation Scaffold. Protein Eng. 1993, 6, 745-754.
11. Zhao, B.; Helms, L. R.; DesJarlais, R. L.; Abdel-Meguid, S.; Wetzel, R. A Paradigm for Drug Discovery Using a Conformation from the Crystal Structure of a Presentation Scaffold. Nature Struct. Biol. 1995, 2, 1131-1137.
12. Kopple, K. D.; Baures, P. W.; Bean, J. W.; D'Ambrosio, C. A.; Hughes, J. L.; Peishoff, C. E.; Eggleston, D. S. Conformation of Arg-Gly-Asp Containing Heterodetic Cyclic Peptides: Solution and Crystal Studies. J. Am. Chem. Soc. 1992, 114, 9615-9623.
13. Bach, A. C., II; Eyermann, C. J.; Gross, J. D.; Bower, M. J.; Harlow, R. L.; Weber, P. C.; DeGrado, W. F. Structural Studies of a Family of High Affinity Ligands for GPIIb/IIIa. J. Am. Chem. Soc. 1994, 116, 3207-3219.
14. Peishoff, C. E.; Ali, F. E.; Bean, J. W.; Calvo, R.; D'Ambrosio, C. A.; Eggleston, D. S.; Hwang, S. M.; Kline, T. P.; Koster, P. F.; Nichols, A.; Powers, D.; Romoff, T.; Samanan, J. M.; Stadel, J.; Vasko, J. A.; Kopple, K. D. Investigation of Conformational Specificity of GPIIb/IIIa: Evaluation of Conformationally Constrained RGD Peptides. J. Med. Chem. 1992, 35, 3962.
15. Eldred, C. D.; Evans, B.; Hindley, S.; Judkins, B. D.; Kelly, H. A.; Kitchin, J.; Lumley, P.; Porter, B.; Ross, B. C.; Smith, K. J.; Taylor, N. R.; Wheatcroft, J. R. Orally Active Non-peptide Fibrinogen Receptor (GPIIbAIIa) Antagonists: Identification of 4-[4-[4-(Ammoimidomethyl)-phenyl]-1-piperazinyl]-1-piperidineacetic Acid as a Long Acting, Broad Spectrum Antithrombotic Agent. J. Med. Chem. 1994, 37, 3882-3885.
16. Ku, T. W.; Ali, F. E.; Barton, L. S.; Bean, J. W.; Bondinell, W. E.; Burgess, J. L.; Callahan, J. F.; Calvo, R. R.; Chen, L.; Eggleston, D. S.; Gleason, J. G.; Huffmann, W. F.; Hwang, S. M.; Jakas, D. R.; Karash, C. B.; Keenan, R. M.; Kopple, K. D.; Miller, W. H.; Newlander, K. A.; Nichols, A.; Parker, M. F.; Peishoff, C. E.; Samanen, J. M.; Uzinskas, I.; Venslavsky, J. W. Direct Design of a Potent Non-peptide Fibrinogen Receptor Antagonist Based on the Structure and Conformation of a Highly Constrained Cyclic RGD Peptide. J. Am. Chem. Soc. 1993, 115, 8861.
17. Bridson, P. K.; Kurtz, H. H. An NMR and computational study of diazepinediones J. Mol. Struct. (Theochem) 1989, 199, 175-181.
18. Williams, D. H.; Fleming, I. Spectroscopic Methods in Organic Chemistry, 3rd ed.; Pergamon Press: Oxford, 1980; p 120.
19. 20
20. Gilman, N. W.; Rosen, P.; Earley, J. V.; Cook, C.; Todaro, L. J. Atropisomers of 1,4-Benzodiazepines. Synthesis and Resolution of a Diazepam-related 1,4-Benzodiazepine. J. Am. Chem. Soc. 1990, 112, 3969.
21. (a) Davies, S. G.; Ichihara, O. Asymmetric Synthesis of R-β-Amino Butanoic Acid and S-β-Tyrosine: Homochiral Lithium Amide Equivalents for Michael Additions to α,β-Unsaturated Esters. Tetrahedron: Asymmetry 1991, 2, 183.
22. (b) (R)- and (S)-3-Aminobutanoate ethyl esters are commerically available from Oxford Asymmetry, U.K. Furthermore, the (R)-3-aminobutanoate benzyl ester is available from Celgene.
23. Alig, L.; Edenhofer, A.; Hadváry, P.; Hürzeler, M.; Knopp, D.; Müller, M.; Steiner, B.; Trzeciak, A.; Weller, T. Low Molecular Weight, Non-peptide fibrinogen Receptor Antagonists. J. Med. Chem. 1992, 35, 4393.
24. Austin, W. B.; Bilow, N.; Kelleghan, W. J.; Lau, K. S. Y. Facile Synthesis of Ethynylated Benzoic Acid Derivatives and Aromatic Compounds via Ethynyltrimethylsilane. J. Org. Chem. 1981, 46, 2280-2286.
25. 6.
26. Meyers, A. I.; Gabel, R. The Displacement of Methoxy by Amino Groups in Aryloxazolines. A Novel Approach to o-Amino-, o-Alkylamino-, o-Dialkylaminobenzoic Acids. J. Org. Chem. 1977, 36, 2653.
27. Bridges, A. J.; Lee, A.; Maduakor, E. C.; Schwartz, C. E. Fluorine as an ortho-Directing Group in Aromatic Metalation: A Two-Step Preparation of Substituted Benzo[b]thiophene-2-carboxylates. Tetrahedron Lett. 1992, 33, 7499.
28. Scarborough, R. M.; Naughton, M.; Hung, D. T.; Rose, J.; Vu, T.-K. H.; Wheaton, V. I.; Turck, C. W.; Coughlin, S. R. Tethered Ligand Agonist Peptides. J. Biol. Chem. 1992, 267, 13146-13149.
29. Allinger, N. L.; Yuh, Y. H. MM2. QCPE 13, 395.
30. Hehre, W. J.; Ditchfield, R.; Pople, J. A. Self-consistent Molecular Orbital Methods. XII. Further Extensions of Gaussian-type Basis Sets for Use in Molecular Orbital Studies of Organic Molecules. J. Chem. Phys. 1972, 56, 2257-2261.
31. Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Gill, P. M. W.; Johnson, B. G.; Robb, M. A.; Cheesman, J. R.; Keith, T. A.; Petersson, G. A.; Montgomery, J. A.; Raghavachari, K.; Al-Laham, M. A.; Zakrzewski, V. G.; Ortiz, J. V.; Foresman, J. B.; Cioslowski, J.; Stefanov, B. B.; Nanayakkara, A.; Challacombe, M.; Peng, C. Y.; Ayala, P. Y.; Chen, W.; Wong, M. W.; Andres, J. L.; Replogle, E. S.; Gomperts, R.; Martin, R. L.; Fox, D. J.; Binkley, J. S.; Defrees, D. J.; Baker, J.; Stewart, J. P.; Head-Gordon, M.; Gonzalez, C.; Pople, J. A. Gaussian 94 (Revision B.3); Gaussian, Inc.: Pittsburgh, PA, 1995; Vol. 1995.
32. Pierschbaker, M. D.; Ruoslahti, E. Influence of Stereochemistry on the Sequence Arg-Gly-Asp-Xaa on Binding in Cell Adhesion. J. Biol. Chem. 1987, 262, 17294.
33. Zablocki, J. A.; Rico, J. G.; Garland, R. B.; Rogers, T. E.; Williams, K.; Schretzman, L.; Rao, S. A.; Bovy, P. R.; Tjoeng, F. S.; Lindmark, R. J.; Toth, M. V.; Zopec, M. E.; McMackins, D. E.; Adams, S. P.; Miyano, M.; Markos, C. S.; Milton, M. N.; Paulson, S.; Herin, M.; Jacqmin, P.; Nicholson, N. S.; Panzer-Knodle, S. G.; Haas, N. F.; Page, J. D.; Szalony, J. A.; Taite, B. B.; Salyers, A. K.; King, L. W.; Campion, J. G.; Feigen, L. P. Potent in vitro and in vivo Inhibitors of Platelet Aggregation Based Upon the Arg-Gly-Asp Sequence in Fibrinogen. (Aminobenzamido)succinyl (ABAS) Series of Orally Active Fibrinogen Receptor Antagonists J. Med. Chem. 1995, 38, 2378.
34. Duggan, M. E.; Naylor-Olsen, A. M.; Perkins, J. J.; Anderson, P. S.; Chang, C. T.-C.; Cook, J. J.; Gould, R. J.; Ihle, N. C.; Hartman, G. D.; Lynch, J. J.; Lynch, R. J.; Manno, P. D.; Schaffer, L. W.; Smith, R. L. Non-peptide Fibrinogen Receptor Antagonists. 7. Design and Synthesis of a Potent, Orally Active Fibrinogen Receptor Antagonist. J. Med. Chem. 1995, 38, 3332-3341.
35. Bondinell, W. E.; Keenan, R. M.; Miller, W. H.; Ali, F. E.; Allen, A. C.; DeBrosse, C. W.; Eggleston, D. S.; Erhard, K. E.; Haltiwanger, R. C.; Huffamnn, W. F.; Hwang, S.-M.; Jakas, D. R.; Koster, P. F.; Ku, T. W.; Lee, C. P.; Nichols, A. J.; Ross, S. T.; Samanen, J. M.; Valocik, R. E.; Vask-Moser, J. A.; Vanslausky, J. W.; Wong, A. S.; Yuan, G. K. Design of a Potent and Orally Active Nonpeptide Platelet Fibrinogen Receptor (GPIIb/ IIIa) Antagonist. Bioog. Med. Chem. 1994, 3, 897-908.
36. Stilz, H. U.; Jablonka, B.; Just, M.; Knolle, J.; Paulus, B. F.; Zoller, G. Discovery of an Orally Active Non-peptide Fibrinogen Receptor Antagonist. J. Med. Chem. 1996, 39, 2118-2122.
37. Eliel, E. L. Stereochemistry of Carbon Compounds; McGraw-Hill, New York, 1962.
38. Atkins, P. W. Physical Chemistry, 2nd ed.; W. H. Freeman: San Francisco, CA, 1982.
39. Ku, T. W.; Miller, W. H.; Bondinell, W. E.; Erhard, K. F.; Keenan, R. M.; Nichols, A. J.; Peishoff, C. E.; Samanen, J. M.; Wong, A. S.; Huffman, W. F. Potent Non-peptide Fibrinogen Receptor Antagonists Which Present an Alternative Pharmacophore. J. Med. Chem. 1995, 38, 9-12.
40. Rahman, S.; Lu, X.; Kakkar, V. V.; Authi, K. S. The integrin alpha IIb beta 3 contains distinct and interacting binding sites for snake-venom RGD (Arg-Gly-Asp) proteins. Evidence that the receptor-binding characteristics of snake-venom RGD proteins are related to the amino acid environment flanking the sequence RGD. Biochem. J. 1995, 312, 223-232.
41. Lu, X.; Rahman, S.; Kakkar, V. V.; Authi, K. S. Substitution of Proline 42 to Alanine and Methionine 42 to Asparagine around the RGD Domain of the Neurotoxin Dendroaspin Alter its Preferential Antagonism to that Resembling the Disintegrin Elegantin. J. Biol. Chem. 1996, 271, 289-294.
42. Kouns, W. C.; Kirchhofer, D.; Hadváry, P.; Edenhofer, A.; Weller, T.; Pfenninger, G.; Baumgartner, H. R.; Jennings, L. K.; Steiner, B. Reversible Conformational Changes Induced in Glycoprotein IIb-IIIa by a Potent and Selective Peptidomimetic Inhibitor. Blood 1993, 80, 2539-2547.
43. Kouns, W. C.; Hadváry, P.; Haering, P.; Steiner, B. Conformational Modulation of Purified Glycoprotein (GP) IIb-IIIa Allows Proteolytic Generation of Active Fragments from Either Active or Inactive GPIIb-IIIa. J. Biol. Chem. 1992, 267, 18844-18851.
44. Calvete, J. J. Clues for Understanding the Structure and Function of a Prototypic Human Integrin: The Platelet Glycoprotein IIb/IIIa Complex. Thromb. Haemost. 1994, 72, 1-15.
45. Du, X.; Plow, E. F.; Frelinger, A. L, III; O'Toole, T. E.; Loftus, J. C.; Ginsberg, M. H. Ligands "Activate" Integrin αIIbβ3 (Platelet GPIIb-IIIa). Cell 1991, 65, 409-416.
46. Mayo, K. H.; Fan, F.; Beavers, M. P.; Eckardt, A.; Keane, P.; Hoekstra, W. J.; Andrade-Gordon, P. RGD Induces Conformational Transition in Purified Platelet Integrin GPIIb/IIIa-SDS System Yielding Multiple Binding States for Fibrinogen γ-Chain C-terminal Peptide. FEBS Lett. 1996, 378, 79-82.
47. Mayo, K. H.; Fan, F.; Beavers, M. P.; Eckardt, A.; Keane, P.; Hoekstra, W. J.; Andrade-Gordon, P. Integrin Receptor GPIIb/ IIIa Bound State Conformation of the γ-Chain C-terminal Peptide 400-411: NMR and Transfer NOE Studies. Biochemistry 1996, 35, 4434-4444.
48. McLane, M. A.; Kowalska, M. A.; Silver, L.; Shattil, S. J.; Niewiarowski, S. Interactions of Disintegrins with the αIIbβ3 Receptor on Resting and Activated Human Platelets. Biochem. J. 1994, 301, 429.
49. Collen, D.; Lu, H. R.; Stassen, J. M.; Vreys, I.; Yasuda, T.; Bunting, S.; Gold, H. K. Antithrombotic Effects and Bleeding Time Prolongation with Synthetic Platelet GPIIb/IIIa Inhibitors in Animal Models of Platelet-mediated Thrombosis. Thromb. Haemost. 1994, 71, 95-102.